BioCryst Pharma (BCRX) Does First Patient in BCX7353 APeX-1 Study
Tweet Send to a Friend
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it has dosed the first subject in the APeX-1 clinical trial of BCX7353 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
